Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the BREVACTA study of RoACTEMRA (tocilizumab, known as ACTEMRA outside Europe) given as a subcutaneous (SC) injection to patients with ...

Roche receives EU approval for new subcutaneous formulation of RoACTEMRA providing more treatment flexibility for patients with moderate to severe rheumatoid arthritis First anti IL-6 receptor ...

Approximately 80% of SSc patients may be affected by interstitial lung disease (ILD), a progressive disease that can significantly impact lung function and can be life-threatening In a global study, ...

Patients with rheumatoid arthritis (RA) in Europe are a giant step closer to receiving access to a subcutaneous formulation of Roche/Chugai's RoActemra, following the thumbs up from the European ...

Roche is celebrating two new approvals in the EU, including Actemra/RoActemra (tocilizumab), which becomes the first therapy approved in Europe to treat giant cell arthritis (GCA). GCA is a chronic ...

(RTTNews) - Roche (RHHBY) said FDA has approved Actemra/RoActemra subcutaneous injection for slowing the rate of decline in pulmonary function in adult patients with systemic sclerosis-associated ...

The study is the first global, randomised, double-blind, placebo-controlled phase III trial investigating Actemra/RoActemra in this setting Roche remains committed to continuing the Actemra/RoActemra ...

Systemic sclerosis (SSc) is a rare disease that affects about 2.5 million people worldwide Approximately 80% of SSc patients may be affected by interstitial lung disease (ILD), a progressive disease ...